<DOC>
	<DOCNO>NCT00370357</DOCNO>
	<brief_summary>The purpose study determine SPL7013 Gel ( VivaGel™ ) safe apply topically day seven consecutive day shaft glans penis healthy male volunteer . The study compare safety SPL7013 Gel penile epithelium urethral mucosa safety placebo gel . The study also assess systemic safety SPL7013 Gel , systemic absorption active ingredient SPL7013 Gel , acceptability study product male volunteer .</brief_summary>
	<brief_title>SPL7013 Gel - Male Tolerance Study</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Provision write informed consent Healthy male age 18 year old HIV negative Reports vaginal intercourse past 12 month Agrees abstain vaginal , anal ( receptive insertive ) oral sexual intercourse , agree refrain masturbation 7 day product use EndofTreatment ( Day 7 ) study visit Known suspect allergy component study product similar ingredient product History significant drug reaction allergy Recent history ( within 12 month ) presence screen contact dermatitis dermatological condition Recent history ( within three month Screening ) sexually transmit infection ( STI ) Current sign symptom UTI and/or STI Screening Baseline Positive urine leukocyte esterase test ( ≥ trace ) Biochemical and/or haematological parameter outside laboratory 's normal reference range Screening Evidence genital piercing , ulceration , genital dermatosis , tinea cruris dermatological condition genitalia upper thigh Genital pain discomfort Screening Baseline Any abnormal finding physical examination medical condition</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>Microbicide</keyword>
	<keyword>SPL7013</keyword>
	<keyword>VivaGel</keyword>
</DOC>